Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Cycloastragenol (TA-65)

Cycloastragenol (TA-65) · also known as Cycloastragenol, TA-65, Triterpenoid saponin aglycone, Astragalus extract

In animal and cell studies, cycloastragenol can affect telomerase-related markers. Results from human randomized trials are inconsistent. In the low-dose group, telomere length in blood cells increased somewhat, but telomerase activity showed no significant difference between groups. Telomerase activation in humans has not been established.

Typical dose: A common supplement dose is 5–25 mg/day, taken on an empty stomach in the morning. This is not an established standard anti-aging dose, and long-term safety and cancer-related risk remain uncertain.
Absorption and forms: Cycloastragenol is a sapogenin obtained by removing the sugar groups from astragaloside IV. Its molecular structure is simpler than astragaloside IV, but its molecular weight is not halved, and an oral absorption advantage cannot be assumed on the basis of fat solubility alone.

Clinical uses and human evidence

Body weight and body fat

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Fernandez 2018 · Curr Pharm Des · Randomized crossover trial · n=40 — TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic Syndrome

Inflammation markers (such as CRP)

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Bawamia 2023 · Geroscience · RCT · n=90 — Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction
  2. Fernandez 2018 · Curr Pharm Des · Randomized crossover trial · n=40 — TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic Syndrome

Mechanisms of action

Mild telomerase reverse transcriptase (TERT) activation and telomere stabilization

★★★☆☆Mechanism evidence: grade CPrimary target

Animal and cell studies suggest that cycloastragenol can affect TERT-related telomerase expression. In human randomized trials, mean telomere length in blood cells increased in the low-dose group, while the high-dose group did not reach statistical significance. Telomerase activity at 12 months did not differ significantly between groups, so telomerase activation in humans has not been established.

References (3)
  1. De Jesus et al. 2011 · Mouse study: TERT levels and short-telomere markers changed in some tissues
  2. Salvador et al. 2016 · Human randomized trial: mean telomere length in blood cells increased in the low-dose group; high-dose results did not reach significance
  3. Bawamia et al. 2023 · Human randomized trial: no significant between-group difference in telomerase activity at 12 months

Safety and drug interactions

Use with caution in people with active cancer or a history of untreated cancer. Telomerase activation is potentially double-edged, and the tumor microenvironment needs careful assessment. The safety of long-term use and the cancer-related risk are unclear, so use it only after a doctor has assessed you.

Immune stimulation

Has immunomodulating effects. Each of these stimulates immune responses. They may counteract immunosuppressant drugs, and caution is also needed during active autoimmune disease.

Open in the interactive app ›